Sangamo Therapeutics Company Profile (NASDAQ:SGMO)

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:SGMO
CUSIP: 80067710
Web: www.sangamo.com

Capitalization:

Market Cap: $1.19564 billion
Outstanding Shares: 83,610,000

Average Prices:

50 Day Moving Avg: $11.44
200 Day Moving Avg: $7.79
52 Week Range: $2.65 - $15.05

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -17.19
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $23.42 million
Price / Sales: 49.09
Book Value: $2.32 per share
Price / Book: 5.93

Profitability:

EBIDTA: ($57,470,000.00)
Net Margins: -246.39%
Return on Equity: -38.49%
Return on Assets: -30.67%

Debt:

Debt-to-Equity Ratio: 0.02%
Current Ratio: 6.14%
Quick Ratio: 6.14%

Misc:

Average Volume: 1.63 million shs.
Beta: 3.15
Short Ratio: 8.11

Frequently Asked Questions for Sangamo Therapeutics (NASDAQ:SGMO)

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its earnings results on Wednesday, August, 9th. The company reported ($0.17) EPS for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.06. The business had revenue of $8.30 million for the quarter, compared to analysts' expectations of $5.82 million. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The business's revenue was up 124.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. View Sangamo Therapeutics' Earnings History.

When will Sangamo Therapeutics make its next earnings announcement?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Sangamo Therapeutics.

Where is Sangamo Therapeutics' stock going? Where will Sangamo Therapeutics' stock price be in 2017?

5 brokers have issued 1-year price targets for Sangamo Therapeutics' stock. Their predictions range from $4.00 to $30.00. On average, they anticipate Sangamo Therapeutics' share price to reach $15.00 in the next year. View Analyst Ratings for Sangamo Therapeutics.

What are analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:

1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (8/18/2017)
2. Cowen and Company analysts commented, "We hosted a group lunch meeting with SGMO management this week." (3/22/2017)
3. Piper Jaffray Companies analysts commented, "Today Sangamo reported 4Q16 financial results, ending the quarter with ~$143M in cash. With updated 2017 guidance on operating expenses incorporated into our model, we expect this cash runway can fund the company through 1H18. This period should include the first safety and biomarker data from early cohorts of patients treated in its open, or soon-to-be opened, clinical trials for Hem A, Hem B, MPS I, and MPS II. Although we expect these early results in late'17/early '18 to focus primarily on safety and pharmacodynamic signals of activity and thus not yet be definitive for informing pivotal programs, we nonetheless believe this progress to be critical for evaluating turn-around efforts and establishing a new era of clinical achievement for Sangamo. That said, in advance of enrollment updates and increased visibility on clinical progress for Sangamo's broadening but early pipeline, we remain on the sidelines with a Neutral rating." (2/28/2017)

Who are some of Sangamo Therapeutics' key competitors?

Some companies that are related to Sangamo Therapeutics include Halozyme Therapeutics (HALO), Loxo Oncology (LOXO), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), Array BioPharma (ARRY), NovoCure Limited (NVCR), Aerie Pharmaceuticals (AERI), Intercept Pharmaceuticals (ICPT), MyoKardia (MYOK), Acceleron Pharma (XLRN), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), Epizyme (EPZM), Dynavax Technologies Corporation (DVAX), Clinigen Group PLC (CLIN), Dermira (DERM), Acorda Therapeutics (ACOR) and Xencor (XNCR).

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:

Alexander Macrae, President, Chief Executive Officer, Director
Kathy Yi, Chief Financial Officer, Senior Vice President
Dale G. Ando M.D., Vice President - Therapeutic Development, Chief Medical Officer
Roger Jeffs, Director
H. Stewart Parker, Director
William R. Ringo Jr., Director
Joseph S. Zakrzewski, Director
Stephen G. Dilly M.D. Ph.D., Independent Director

Who owns Sangamo Therapeutics stock?

Sangamo Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wasatch Advisors Inc. (9.63%), Vanguard Group Inc. (4.83%), EcoR1 Capital LLC (3.57%), State Street Corp (2.60%), FMR LLC (2.24%) and RA Capital Management LLC (1.74%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Who sold Sangamo Therapeutics stock? Who is selling Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Candriam Luxembourg S.C.A., TIAA CREF Investment Management LLC, Keybank National Association OH, Tocqueville Asset Management L.P., Wedbush Securities Inc., Bourgeon Capital Management LLC and Franklin Street Advisors Inc. NC. Company insiders that have sold Sangamo Therapeutics stock in the last year include Curt A Herberts III and William R Ringo. View Insider Buying and Selling for Sangamo Therapeutics.

Who bought Sangamo Therapeutics stock? Who is buying Sangamo Therapeutics stock?

Sangamo Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, RA Capital Management LLC, State Street Corp, Vanguard Group Inc., Balyasny Asset Management LLC, DAFNA Capital Management LLC, Federated Investors Inc. PA and Wells Fargo & Company MN. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy Sangamo Therapeutics stock?

Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of Sangamo Therapeutics stock can currently be purchased for approximately $13.75.

MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		191 (Vote Outperform)
Underperform Votes:		143 (Vote Underperform)
Total Votes:		334

MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Sangamo Therapeutics (NASDAQ:SGMO) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	2 Hold Ratings, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.60)
Consensus Price Target:	$15.00 (9.09% upside)

Analysts' Ratings History for Sangamo Therapeutics (NASDAQ:SGMO)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/14/2017	Jefferies Group LLC	Reiterated Rating	Buy	$18.00	High
9/5/2017	Wells Fargo & Company	Reiterated Rating	Outperform	$20.00 -> $30.00	Low
8/10/2017	Piper Jaffray Companies	Set Price Target	Hold	$8.00	High
5/16/2017	Wedbush	Reiterated Rating	Neutral	$6.00 -> $4.00	Medium
3/22/2017	Cowen and Company	Reiterated Rating	Buy		High
8/4/2016	Janney Montgomery Scott	Downgrade	Buy -> Neutral	$15.00 -> $8.00	N/A
2/10/2016	J P Morgan Chase & Co	Reiterated Rating	Overweight	$16.00	N/A

(Data available from 9/23/2015 forward)

Earnings History for Sangamo Therapeutics (NASDAQ:SGMO)

Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Earnings History by Quarter for Sangamo Therapeutics (NASDAQ SGMO)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/24/2017		($0.19)					N/A
8/9/2017	Q2 2017	($0.23)	($0.17)	$5.82 million	$8.30 million	View	Listen
5/10/2017	Q1 2017	($0.26)	($0.23)	$4.14 million	$3.40 million	View	N/A
2/28/2017	Q416	($0.26)	($0.14)	$3.91 million	$8.90 million	View	Listen
10/26/2016	Q316	($0.25)	($0.27)	$4.24 million	$2.82 million	View	Listen
8/3/2016	Q216	($0.24)	($0.38)	$5.38 million	$3.70 million	View	N/A
5/2/2016	Q116	($0.24)	($0.23)	$5.49 million	$3.94 million	View	N/A
2/9/2016	Q415	($0.21)	($0.20)	$9.86 million	$9.10 million	View	N/A
10/28/2015	Q315	($0.25)	($0.13)	$13.09 million	$8.57 million	View	Listen
8/5/2015	Q215	($0.13)	($0.17)	$14.72 million	$8.36 million	View	Listen
4/22/2015	Q115	($0.13)	($0.08)	$12.50 million	$13.50 million	View	Listen
2/10/2015	Q414	($0.09)	($0.06)	$14.50 million	$15.00 million	View	N/A
10/22/2014	Q314	($0.04)	($0.11)	$8.27 million	$12.40 million	View	Listen
7/23/2014	Q214	($0.14)	($0.10)	$7.84 million	$10.38 million	View	Listen
5/6/2014	Q114	($0.13)	($0.12)	$6.59 million	$8.10 million	View	Listen
2/11/2014	Q413	($0.10)	($0.13)	$8.90 million	$6.90 million	View	Listen
10/23/2013	Q313	($0.11)	($0.11)	$5.52 million	$5.70 million	View	N/A
7/24/2013	Q2 2013	($0.12)	($0.10)	$4.77 million	$6.90 million	View	N/A
5/8/2013	Q1 2013	($0.17)	($0.13)	$3.79 million	$4.60 million	View	N/A
2/6/2013	Q4 2012	($0.12)	($0.07)	$5.95 million	$8.93 million	View	N/A
10/24/2012	Q312	($0.14)	($0.11)	$3.80 million	$4.90 million	View	N/A
7/25/2012		($0.15)	($0.11)			View	N/A
5/2/2012		($0.16)	($0.14)			View	N/A
10/25/2011		($0.16)	($0.18)			View	N/A
7/27/2011		($0.16)	($0.20)			View	N/A
4/26/2011		($0.17)	($0.21)			View	N/A
2/2/2011		($0.19)	($0.18)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

2017 EPS Consensus Estimate: ($0.87)
2018 EPS Consensus Estimate: ($0.98)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	2	($0.25)	($0.23)	($0.24)
Q2 2017	2	($0.23)	($0.12)	($0.18)
Q3 2017	2	($0.22)	($0.21)	($0.22)
Q4 2017	2	($0.25)	($0.23)	($0.24)
Q1 2018	1	($0.25)	($0.25)	($0.25)
Q2 2018	1	($0.25)	($0.25)	($0.25)
Q3 2018	1	($0.24)	($0.24)	($0.24)
Q4 2018	1	($0.24)	($0.24)	($0.24)

(Data provided by Zacks Investment Research)

Dividend History for Sangamo Therapeutics (NASDAQ:SGMO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Sangamo Therapeutics (NASDAQ:SGMO)

Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 63.43%

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/20/2017	William R Ringo	Director	Sell	31,000	$14.37	$445,470.00
9/1/2017	Curt A Herberts III	VP	Sell	15,000	$15.00	$225,000.00
8/14/2017	Curt A Herberts III	VP	Sell	11,474	$10.44	$119,788.56
7/14/2017	Curt A Herberts III	VP	Sell	15,000	$10.00	$150,000.00
6/1/2017	Curt A. Herberts III	VP	Sell	2,000	$6.80	$13,600.00
5/12/2017	Curt A. Herberts III	VP	Sell	2,639	$8.02	$21,164.78
8/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	27,770	$12.82	$356,011.40
7/30/2015	Ra Capital Management, Llc	Major Shareholder	Sell	109,590	$12.42	$1,361,107.80
7/29/2015	Ra Capital Management, Llc	Major Shareholder	Sell	1,407	$12.41	$17,460.87
7/28/2015	Ra Capital Management, Llc	Major Shareholder	Sell	60,081	$12.11	$727,580.91
7/25/2015	Ra Capital Management, Llc	Major Shareholder	Sell	47,429	$12.31	$583,850.99
7/24/2015	Ra Capital Management, Llc	Major Shareholder	Sell	124,050	$12.28	$1,523,334.00
7/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	37,215	$12.26	$456,255.90
7/15/2015	Edward O Lanphier II	CEO	Sell	25,000	$10.43	$260,750.00
7/13/2015	Henry Ward Wolff	CFO	Sell	12,000	$10.00	$120,000.00
7/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	82,700	$16.01	$1,324,027.00
6/16/2015	Ra Capital Management, Llc	Major Shareholder	Sell	250,500	$16.55	$4,145,775.00
6/9/2015	Ra Capital Management, Llc	Major Shareholder	Sell	83,500	$15.50	$1,294,250.00
6/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	135,101	$14.29	$1,930,593.29
6/5/2015	Dale G Ando	CMO	Sell	15,000	$12.29	$184,350.00
6/5/2015	Ra Capital Management, Llc	Major Shareholder	Sell	115,102	$14.13	$1,626,391.26
6/4/2015	Ra Capital Management, Llc	Major Shareholder	Sell	70,640	$13.10	$925,384.00
6/3/2015	Ra Capital Management, Llc	Major Shareholder	Sell	76,833	$12.86	$988,072.38
6/3/2015	William R Ringo	Director	Sell	2,200	$12.44	$27,368.00
6/1/2015	Philip D Gregory	SVP	Sell	15,000	$12.39	$185,850.00
5/30/2015	Ra Capital Management, Llc	Major Shareholder	Sell	65,884	$13.40	$882,845.60
5/29/2015	Ra Capital Management, Llc	Major Shareholder	Sell	155,675	$13.53	$2,106,282.75
5/28/2015	Ra Capital Management, Llc	Major Shareholder	Sell	148,689	$13.43	$1,996,893.27
5/27/2015	Ra Capital Management, Llc	Major Shareholder	Sell	263,437	$13.55	$3,569,571.35
5/23/2015	Ra Capital Management, Llc	Major Shareholder	Sell	51,597	$13.27	$684,692.19
5/22/2015	Ra Capital Management, Llc	Major Shareholder	Sell	56,396	$13.56	$764,729.76
5/13/2015	Ra Capital Management, Llc	Major Shareholder	Sell	56,060	$13.12	$735,507.20
5/12/2015	Ra Capital Management, Llc	Major Shareholder	Sell	29,659	$13.03	$386,456.77
5/8/2015	Ra Capital Management, Llc	Major Shareholder	Sell	83,300	$12.40	$1,032,920.00
5/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	35,736	$12.09	$432,048.24
5/5/2015	Dale G Ando	CMO	Sell	15,000	$12.29	$184,350.00
5/4/2015	William R Ringo	Director	Sell	3,000	$12.98	$38,940.00
4/30/2015	Ra Capital Management, Llc	Major Shareholder	Buy	124,500	$13.45	$1,674,525.00
4/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	74,844	$13.29	$994,676.76
4/25/2015	Ra Capital Management, Llc	Major Shareholder	Buy	166,000	$13.63	$2,262,580.00
4/22/2015	Ra Capital Management, Llc	Major Shareholder	Sell	352,750	$14.86	$5,241,865.00
4/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	41,500	$14.02	$581,830.00
4/16/2015	Ra Capital Management, Llc	Major Shareholder	Sell	21,829	$14.09	$307,570.61
4/15/2015	Edward O Lanphier II	CEO	Sell	25,000	$15.33	$383,250.00
4/15/2015	Ra Capital Management, Llc	Major Shareholder	Buy	21,829	$13.16	$287,269.64
4/14/2015	Ra Capital Management, Llc	Major Shareholder	Sell	3,055	$14.78	$45,152.90
4/11/2015	Ra Capital Management, Llc	Major Shareholder	Buy	116,992	$14.48	$1,694,044.16
4/10/2015	Henry Ward Wolff	CFO	Sell	12,000	$15.31	$183,720.00
4/10/2015	Ra Capital Management, Llc	Major Shareholder	Buy	83,000	$14.91	$1,237,530.00
4/9/2015	Ra Capital Management, Llc	Major Shareholder	Sell	69,856	$16.27	$1,136,557.12
4/8/2015	Ra Capital Management, Llc	Major Shareholder	Buy	121,876	$15.49	$1,887,859.24
4/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	33,667	$15.42	$519,145.14
4/6/2015	Dale G Ando	CMO	Sell	15,000	$14.94	$224,100.00
4/6/2015	William R Ringo	Director	Sell	2,200	$14.95	$32,890.00
4/4/2015	Ra Capital Management, Llc	Major Shareholder	Buy	179,031	$15.38	$2,753,496.78
4/3/2015	Ra Capital Management, Llc	Major Shareholder	Buy	195,126	$16.61	$3,241,042.86
4/1/2015	Philip D Gregory	SVP	Sell	15,000	$15.15	$227,250.00
4/1/2015	Ra Capital Management, Llc	Major Shareholder	Sell	250,000	$18.01	$4,502,500.00
3/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	84,000	$17.10	$1,436,400.00
3/27/2015	Ra Capital Management, Llc	Major Shareholder	Buy	256,187	$17.65	$4,521,700.55
3/26/2015	Ra Capital Management, Llc	Major Shareholder	Buy	210,013	$18.14	$3,809,635.82
3/25/2015	Ra Capital Management, Llc	Major Shareholder	Buy	84,000	$19.42	$1,631,280.00
3/21/2015	Ra Capital Management, Llc	Major Shareholder	Buy	101,808	$21.22	$2,160,365.76
3/19/2015	Henry Ward Wolff	CFO	Sell	10,000	$18.00	$180,000.00
3/19/2015	Ra Capital Management, Llc	Major Shareholder	Sell	17,808	$24.28	$432,378.24
3/18/2015	Ra Capital Management, Llc	Major Shareholder	Sell	84,000	$23.74	$1,994,160.00
3/17/2015	Ra Capital Management, Llc	Major Shareholder	Buy	52,161	$23.02	$1,200,746.22
3/16/2015	Edward O Lanphier II	CEO	Sell	25,000	$17.29	$432,250.00
3/13/2015	Ra Capital Management, Llc	Major Shareholder	Buy	71,319	$22.76	$1,623,220.44
3/12/2015	Ra Capital Management, Llc	Major Shareholder	Sell	123,480	$23.40	$2,889,432.00
3/10/2015	Ra Capital Management, Llc	Major Shareholder	Buy	12,522	$22.30	$279,240.60
3/7/2015	Ra Capital Management, Llc	Major Shareholder	Buy	258,377	$22.25	$5,748,888.25
3/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	61,483	$24.10	$1,481,740.30
3/3/2015	Ra Capital Management, Llc	Major Shareholder	Sell	84,000	$18.21	$1,529,640.00
3/3/2015	William R Ringo	Director	Sell	2,200	$17.21	$37,862.00
3/2/2015	Philip D Gregory	SVP	Sell	15,000	$17.26	$258,900.00
2/28/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.10	$760,200.00
2/27/2015	Ra Capital Management, Llc	Major Shareholder	Sell	32,196	$19.37	$623,636.52
2/26/2015	Ra Capital Management, Llc	Major Shareholder	Buy	74,194	$19.57	$1,451,976.58
2/20/2015	Ra Capital Management, Llc	Major Shareholder	Sell	35,319	$18.40	$649,869.60
2/19/2015	Ra Capital Management, Llc	Major Shareholder	Sell	6,720	$18.51	$124,387.20
2/18/2015	Ra Capital Management, Llc	Major Shareholder	Sell	11,172	$18.11	$202,324.92
2/14/2015	Ra Capital Management, Llc	Major Shareholder	Sell	15,380	$18.61	$286,221.80
2/13/2015	Ra Capital Management, Llc	Major Shareholder	Sell	15,409	$18.46	$284,450.14
2/12/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.04	$757,680.00
2/12/2015	Saira Ramasastry	Director	Sell	10,000	$15.00	$150,000.00
2/11/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$19.65	$825,300.00
2/7/2015	Ra Capital Management, Llc	Major Shareholder	Sell	34,688	$18.52	$642,421.76
2/6/2015	Ra Capital Management, Llc	Major Shareholder	Sell	7,312	$18.42	$134,687.04
2/5/2015	Dale G Ando	CMO	Sell	15,000	$12.93	$193,950.00
2/5/2015	Ra Capital Management, Llc	Major Shareholder	Buy	42,000	$18.23	$765,660.00
2/3/2015	William R Ringo	Director	Sell	2,200	$12.70	$27,940.00
2/2/2015	Philip D Gregory	SVP	Sell	15,000	$12.86	$192,900.00
1/16/2015	Edward O Lanphier II	CEO	Sell	25,000	$14.22	$355,500.00
1/12/2015	Henry Ward Wolff	CFO	Sell	12,000	$15.87	$190,440.00
1/5/2015	Dale G Ando	CMO	Sell	15,000	$15.19	$227,850.00
1/5/2015	William R Ringo	Director	Sell	2,200	$15.20	$33,440.00
12/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$15.40	$385,000.00
12/15/2014	John William Larson	Director	Sell	10,000	$16.28	$162,800.00
12/9/2014	John William Larson	Director	Sell	10,000	$12.00	$120,000.00
12/1/2014	Philip D Gregory	SVP	Sell	15,000	$11.68	$175,200.00
11/17/2014	Edward O Lanphier II	CEO	Sell	25,000	$11.23	$280,750.00
11/12/2014	John William Larson	Director	Sell	10,000	$12.00	$120,000.00
11/3/2014	Philip D Gregory	SVP	Sell	15,000	$11.91	$178,650.00
10/28/2014	John William Larson	Director	Sell	10,000	$12.02	$120,200.00
10/10/2014	Henry Ward Wolff	CFO	Sell	2,000	$10.10	$20,200.00
10/6/2014	Dale G Ando	CMO	Sell	15,000	$10.72	$160,800.00
10/1/2014	Philip D Gregory	SVP	Sell	15,000	$10.80	$162,000.00
9/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$12.14	$303,500.00
9/10/2014	Henry Ward Wolff	CFO	Sell	2,000	$12.31	$24,620.00
9/5/2014	Dale G Ando	CMO	Sell	15,000	$12.20	$183,000.00
9/4/2014	John William Larson	Director	Sell	10,000	$12.81	$128,100.00
8/15/2014	Edward O Lanphier II	CEO	Sell	25,000	$13.95	$348,750.00
8/11/2014	Henry Ward Wolff	CFO	Sell	10,000	$14.17	$141,700.00
8/5/2014	Dale G Ando	CMO	Sell	15,000	$12.99	$194,850.00
8/4/2014	John William Larson	Director	Sell	10,000	$12.56	$125,600.00
8/1/2014	Philip D Gregory	SVP	Sell	15,000	$12.54	$188,100.00
7/18/2014	Edward O Lanphier II	CEO	Sell	25,000	$12.16	$304,000.00
7/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$13.26	$198,900.00
7/1/2014	Philip D Gregory	SVP	Sell	15,000	$15.66	$234,900.00
6/23/2014	Saira Ramasastry	Director	Sell	5,550	$15.53	$86,191.50
6/16/2014	Edward O Lanphier II	CEO	Sell	25,000	$16.41	$410,250.00
6/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$15.62	$234,300.00
6/2/2014	Philip D Gregory	SVP	Sell	15,000	$12.85	$192,750.00
5/15/2014	Edward Lanphier II	CEO	Sell	25,000	$13.14	$328,500.00
5/1/2014	Philip Gregory	SVP	Sell	15,000	$13.68	$205,200.00
4/28/2014	Dale Ando	CMO	Sell	15,000	$13.64	$204,600.00
4/28/2014	John William Larson	Director	Sell	10,000	$13.48	$134,800.00
4/15/2014	Edward Lanphier II	CEO	Sell	25,000	$14.20	$355,000.00
4/10/2014	Henry Ward Wolff	CFO	Sell	15,000	$15.72	$235,800.00
3/26/2014	Dale Ando	CMO	Sell	15,000	$18.65	$279,750.00
3/21/2014	Philip Gregory	Insider	Sell	15,000	$22.38	$335,700.00
3/17/2014	Edward Lanphier II	CEO	Sell	50,000	$23.22	$1,161,000.00
3/17/2014	Saira Ramasastry	Director	Sell	10,000	$23.26	$232,600.00
3/14/2014	Steven Mento	Director	Sell	6,103	$22.77	$138,965.31
2/18/2014	Edward Lanphier II	CEO	Sell	50,000	$18.09	$904,500.00
1/27/2014	Dale Ando	CMO	Sell	15,000	$18.58	$278,700.00
1/10/2014	Henry Ward Wolff	CFO	Sell	10,000	$18.69	$186,900.00
1/2/2014	Philip Gregory	VP	Sell	15,000	$13.56	$203,400.00
12/26/2013	Dale Ando	CMO	Sell	15,000	$14.37	$215,550.00
11/15/2013	Edward Lanphier II	CEO	Sell	25,000	$10.11	$252,750.00
11/5/2013	Philip D Gregory	VP	Sell	15,000	$9.60	$144,000.00
10/28/2013	Dale G Ando	CMO	Sell	15,000	$10.39	$155,850.00
10/21/2013	Paul B Cleveland	Director	Sell	10,000	$10.93	$109,300.00
10/15/2013	Edward O Lanphier II	CEO	Sell	25,000	$11.32	$283,000.00
10/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$11.28	$112,800.00
10/1/2013	Philip D Gregory	VP	Sell	15,000	$10.54	$158,100.00
9/16/2013	Edward Lanphier II	CEO	Sell	25,000	$11.29	$282,250.00
9/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.86	$108,600.00
9/3/2013	Paul Cleveland	Director	Sell	7,278	$10.30	$74,963.40
9/3/2013	Philip Gregory	VP	Sell	15,000	$10.33	$154,950.00
8/26/2013	Dale Ando	CMO	Sell	15,000	$10.04	$150,600.00
8/15/2013	Edward Lanphier II	CEO	Sell	25,000	$10.12	$253,000.00
8/13/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
8/1/2013	Philip Gregory	VP	Sell	15,000	$9.89	$148,350.00
7/29/2013	Philip D Gregory	VP	Sell	15,000	$10.04	$150,600.00
7/26/2013	Dale G Ando	CMO	Sell	15,000	$10.09	$151,350.00
7/17/2013	Edward O Lanphier II	CEO	Sell	25,000	$10.00	$250,000.00
7/17/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
7/15/2013	Paul B Cleveland	Director	Sell	8,000	$9.59	$76,720.00
6/3/2013	Philip D Gregory	VP	Sell	3,000	$7.88	$23,640.00
5/28/2013	Dale G Ando	CMO	Sell	15,000	$8.32	$124,800.00
4/10/2013	Henry Ward Wolff	CFO	Sell	10,000	$10.00	$100,000.00
12/26/2012	Dale G Ando	CMO	Sell	17,000	$5.92	$100,640.00
12/3/2012	John William Larson	Director	Sell	15,000	$5.64	$84,600.00
9/5/2012	Dale G Ando	CMO	Sell	15,000	$5.60	$84,000.00
9/4/2012	John William Larson	Director	Sell	15,000	$5.30	$79,500.00

(Data available from 1/1/2013 forward)

Headline Trends for Sangamo Therapeutics (NASDAQ:SGMO) Latest Headlines for Sangamo Therapeutics (NASDAQ:SGMO)

Source:

Date	Headline
	Sangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference finance.yahoo.com - September 23 at 6:20 AM
	William R. Ringo Sells 31,000 Shares of Sangamo Therapeutics, Inc. (SGMO) Stock www.americanbankingnews.com - September 22 at 7:52 PM
	Sangamo Therapeutics, Inc. (SGMO) Receives "Buy" Rating from Jefferies Group LLC www.americanbankingnews.com - September 14 at 7:16 PM
	$9.42 Million in Sales Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter www.americanbankingnews.com - September 6 at 11:26 AM
	Sangamo Therapeutics, Inc. (SGMO) Earns Outperform Rating from Wells Fargo & Company www.americanbankingnews.com - September 5 at 3:34 PM
	Today's Research Reports on Stocks to Watch: Sangamo Therapuetics and Nutanix finance.yahoo.com - September 5 at 8:22 AM
	Sangamo Therapeutics, Inc. (SGMO) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - September 2 at 12:36 PM
	Insider Selling: Sangamo Therapeutics, Inc. (SGMO) VP Sells 15,000 Shares of Stock www.americanbankingnews.com - September 1 at 8:04 PM
	Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit finance.yahoo.com - September 1 at 8:37 AM
	Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences finance.yahoo.com - August 31 at 9:59 AM
	Sangamo Therapeutics Initiates Dosing in Hemophilia A Study - Nasdaq www.nasdaq.com - August 30 at 9:07 AM
	Why Abeona Therapeutics Inc. (and Maybe Sangamo Therapeutics, Inc.) Jumped Higher Today www.fool.com - August 29 at 6:52 PM
	Sangamo Biosciences (SGMO), Pfizer (PFE) Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial ... - StreetInsider.com www.streetinsider.com - August 26 at 2:12 AM
	Breakfast Technical Briefing on Biotech Stocks -- Kite Pharma, Novavax, Sangamo Therapeutics, and Spectrum Pharma www.bizjournals.com - August 21 at 8:06 AM
	Sangamo Therapeutics, Inc. (SGMO) Upgraded at Zacks Investment Research www.americanbankingnews.com - August 18 at 6:56 AM
	Sangamo Therapeutics: The Breakthrough In Gene Therapy - Seeking Alpha seekingalpha.com - August 17 at 9:37 PM
	Sangamo Therapeutics (SGMO) Presents At Wedbush PacGrow Healthcare Conference - Slideshow seekingalpha.com - August 17 at 7:30 AM
	Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : August 17, 2017 finance.yahoo.com - August 17 at 7:30 AM
	Brokerages Expect Sangamo Therapeutics, Inc. (SGMO) Will Announce Earnings of -$0.23 Per Share www.americanbankingnews.com - August 16 at 10:28 PM
	Equities Analysts Set Expectations for Sangamo Therapeutics, Inc.'s Q3 2017 Earnings (SGMO) www.americanbankingnews.com - August 16 at 6:30 AM
	Sangamo Therapeutics, Inc. (SGMO) VP Curt A. Herberts III Sells 11,474 Shares www.americanbankingnews.com - August 15 at 8:00 PM
	Sangamo Therapeutics Announces Presentation At The 2017 Wedbush PacGrow Healthcare Conference finance.yahoo.com - August 11 at 8:28 AM
	Sangamo Therapeutics, Inc. (SGMO) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS www.americanbankingnews.com - August 10 at 11:29 PM
	Sangamo Therapeutics, Inc. (SGMO) PT Set at $8.00 by Piper Jaffray Companies www.americanbankingnews.com - August 10 at 9:08 AM
	Sangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - August 10 at 7:49 AM
	Investor Network: Sangamo Therapeutics, Inc. to Host Earnings Call finance.yahoo.com - August 10 at 7:49 AM
	Sangamo Therapeutics Reports Second Quarter 2017 Financial Results finance.yahoo.com - August 10 at 7:49 AM
	Sangamo reports 2Q loss finance.yahoo.com - August 10 at 7:49 AM
	Edited Transcript of SGMO earnings conference call or presentation 9-Aug-17 9:00pm GMT finance.yahoo.com - August 10 at 7:49 AM
	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - August 8 at 12:44 PM
	Sangamo Therapeutics, Inc. (SGMO) Downgraded by BidaskClub to "Sell" www.americanbankingnews.com - August 5 at 10:58 AM
	Sangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast - PR Newswire (press release) www.prnewswire.com - August 4 at 8:08 AM
	Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : August 3, 2017 finance.yahoo.com - August 4 at 8:08 AM
	Sangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast finance.yahoo.com - August 2 at 4:22 PM
	$6.79 Million in Sales Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter www.americanbankingnews.com - July 31 at 9:23 AM
	-$0.24 EPS Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter www.americanbankingnews.com - July 29 at 4:20 PM
	BidaskClub Downgrades Sangamo Therapeutics, Inc. (SGMO) to Hold www.americanbankingnews.com - July 29 at 12:31 PM
	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to Release Quarterly Earnings on Tuesday www.americanbankingnews.com - July 27 at 8:14 PM
	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Cut to Hold at Zacks Investment Research www.americanbankingnews.com - July 18 at 9:21 AM
	Sangamo BioSciences, Inc. (NASDAQ:SGMO) VP Sells $150,000.00 in Stock www.americanbankingnews.com - July 14 at 10:56 PM
	Sangamo BioSciences, Inc. (SGMO) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - July 14 at 12:58 PM
	Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II finance.yahoo.com - July 14 at 8:18 AM
	Sangamo shares rise as metabolic drugs given FDA fast-track status finance.yahoo.com - July 14 at 8:18 AM
	ETFs with exposure to Sangamo Therapeutics, Inc. : July 7, 2017 finance.yahoo.com - July 8 at 8:59 AM
	$6.79 Million in Sales Expected for Sangamo BioSciences, Inc. (SGMO) This Quarter www.americanbankingnews.com - July 7 at 1:26 PM
	Despite This Happening, Sangamo Therapeutics Inc. Surged 31% in June finance.yahoo.com - July 7 at 10:58 AM
	-$0.23 EPS Expected for Sangamo BioSciences, Inc. (SGMO) This Quarter www.americanbankingnews.com - July 5 at 12:34 PM
	Will Sangamo Therapeutics (SGMO) Crush Estimates at Its Next Earnings Report? finance.yahoo.com - July 1 at 7:25 AM
	Sangamo Biosciences (SGMO) Names Roger Jeffs & Joseph ... - StreetInsider.com www.streetinsider.com - June 30 at 6:37 AM
	Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors finance.yahoo.com - June 30 at 6:37 AM